1 Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;2015(4):CD006150.
2 European AIDS Clinical Society. EACS Guidelines version 10.1, October 2020. [06.01.2021]; Available from: https://www.eacsociety.org/files/guidelines-10.1_finaljan2021_1.pdf
3 Bundesamt für Gesundheit. Der HIV-Test auf Initiative des Arztes/der Ärztin. BAG Bulletin 21. 2015;375–9.
4 Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Gunthard HF. Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. Clin Infect Dis. 2015;61(6):1013–21.
5 The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/µL? Clin Infect Dis. 2010;51(5):611–9.
6 Atkinson A, Zwahlen M, Barger D, d’Arminio Monforte A, De Wit S, Ghosn J, et al. on behalf of COHERE. Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE. Clin Infect Dis. 2020;ciaa615.